James Investment Research’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.53M | Sell |
23,867
-204
| -0.8% | -$38.4K | 0.46% | 48 |
|
|
2026
Q1 | $4.75M | Buy |
24,071
+475
| +2% | +$91.6K | 0.53% | 50 |
|
|
2025
Q4 | $4.34M | Sell |
23,596
-6,308
| -21% | -$1.11M | 0.47% | 54 |
|
|
2025
Q3 | $4.59M | Sell |
29,904
-437
| -1% | -$66.1K | 0.5% | 53 |
|
|
2025
Q2 | $4.24M | Sell |
30,341
-2,544
| -8% | -$357K | 0.5% | 53 |
|
|
2025
Q1 | $4.83M | Sell |
32,885
-233
| -0.7% | -$33.7K | 0.61% | 45 |
|
|
2024
Q4 | $4.34M | Sell |
33,118
-8,426
| -20% | -$1.18M | 0.52% | 50 |
|
|
2024
Q3 | $6.47M | Sell |
41,544
-264
| -0.6% | -$42.6K | 0.75% | 40 |
|
|
2024
Q2 | $6.52M | Sell |
41,808
-5,611
| -12% | -$844K | 0.78% | 38 |
|
|
2024
Q1 | $6.43M | Sell |
47,419
-4,597
| -9% | -$609K | 0.76% | 40 |
|
|
2023
Q4 | $7.01M | Sell |
52,016
-445
| -0.8% | -$57.8K | 0.88% | 34 |
|
|
2023
Q3 | $7.11M | Sell |
52,461
-178
| -0.3% | -$24.3K | 0.94% | 28 |
|
|
2023
Q2 | $7.53M | Sell |
52,639
-340
| -0.6% | -$50K | 0.96% | 31 |
|
|
2023
Q1 | $7.35M | Buy |
52,979
+1,231
| +2% | +$166K | 0.97% | 30 |
|
|
2022
Q4 | $7.02M | Sell |
51,748
-1,543
| -3% | -$194K | 0.98% | 28 |
|
|
2022
Q3 | $5.84M | Buy |
53,291
+470
| +0.9% | +$59.6K | 0.83% | 35 |
|
|
2022
Q2 | $6.98M | Sell |
52,821
-480
| -0.9% | -$63K | 0.93% | 29 |
|
|
2022
Q1 | $7.07M | Sell |
53,301
-9,502
| -15% | -$1.14M | 0.74% | 38 |
|
|
2021
Q4 | $7.32M | Sell |
62,803
-2,699
| -4% | -$318K | 0.67% | 47 |
|
|
2021
Q3 | $7.87M | Sell |
65,502
-4,741
| -7% | -$552K | 0.73% | 47 |
|
|
2021
Q2 | $8.41M | Sell |
70,243
-242
| -0.3% | -$26.6K | 0.72% | 51 |
|
|
2021
Q1 | $7.01M | Sell |
70,485
-12,831
| -15% | -$1.29M | 0.64% | 55 |
|
|
2020
Q4 | $8.33M | Sell |
83,316
-6,329
| -7% | -$670K | 0.75% | 39 |
|
|
2020
Q3 | $9.82M | Buy |
89,645
+43,852
| +96% | +$4.88M | 0.91% | 32 |
|
|
2020
Q2 | $4.84M | Buy |
45,793
+45,771
| +208,050% | +$4.73M | 0.45% | 73 |
|
|
2020
Q1 | $2K | Buy |
+22
| New | +$2.07K | ﹤0.01% | 438 |
|
|
2019
Q2 | – | Sell |
-125
| Closed | -$10K | – | 677 |
|
|
2019
Q1 | $10K | Buy |
+125
| New | +$9.85K | ﹤0.01% | 737 |
|
|
2017
Q1 | – | Sell |
-18
| Closed | -$1K | – | 651 |
|
|
2016
Q4 | $1K | Hold |
18
| – | – | ﹤0.01% | 538 |
|
|
2016
Q3 | $1K | Hold |
18
| – | – | ﹤0.01% | 541 |
|
|
2016
Q2 | $1K | Buy |
+18
| New | +$1.04K | ﹤0.01% | 506 |
|
Other funds holding AZN
EP
IA
James Investment Research's AZN Position: Q2 2026 in Review
James Investment Research reduced its AstraZeneca (AZN) stake by 0.85% in Q2 2026, selling an estimated $38.4K and leaving 23,867 shares worth $4.53M. The position accounts for 0.46% of the portfolio, ranked #48.
James Investment Research first reported a position in AZN in Q2 2016 and has held it in 30 quarters since. The position peaked at $9.82M in Q3 2020. 1,498 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- James Investment Research held 23,867 shares of AstraZeneca worth $4.53M as of Q2 2026.
- James Investment Research sold 204 AstraZeneca shares in Q2 2026, an estimated $38.4K.
- AstraZeneca made up 0.46% of James Investment Research's portfolio in Q2 2026, its #48 holding.
- James Investment Research first reported a position in AstraZeneca in Q2 2016 and has held it in 30 quarters since.
- James Investment Research's AstraZeneca position peaked at $9.82M in Q3 2020.
- 1,498 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on James Investment Research's 13F filing for Q2 2026, filed 24 Jul 2026.